Diabetic kidney disease
Conditions
Interventions
Control group:Western medicine standard treatment + Chinese medicine granule simulation agent
Experimental group:Western medicine standard treatment + Qing-Re-Xiao-Zheng-Yi-Qi formula
Sponsors
Dongzhimen Hospital Beijing University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1)Meet the diagnostic criteria of DKD (2)AER 30-300mg/ 24h or ACR 30-300mg/g (or 3-30mg/mmol) (3)eGFR=60ml·min-1·(1.73 m2)-1 (4)HbA1c (glycated hemoglobin) =8.5% (5)18 years = age =75 years (6)TCM syndrome of Qi and Yin deficiency stasis and heat interjunction (7)The subject gives informed consent and signs the informed consent voluntarily.
Exclusion criteria
Exclusion criteria: (1) Non-DKD (rapid deterioration of renal function sudden increase of urinary protein accompanied by survival) was considered in clinical diagnosis Motile urinary sediment etc.) (2) Complications such as severe infection severe anemia electrolyte disturbance occurred within the past 4 weeks (3) renal artery stenosis (4) Serum albumin < 20g/L (5) Accompanied by acute kidney injury oliguria or anuria severe edema massive pleural effusion and abdominal accumulation Liquid person (6) Used glucocorticoids immunosuppressants and tripterygium wilfordis preparations in the past 12 weeks (7) Patients with serious heart brain liver and hematopoietic system diseases within three months: stroke Transient ischemic attack significant neurological dysfunction myocardial infarction and instability after stroke Sexual angina pectoris ischemic heart disease after coronary artery bypass or PCI congestive heart failure (heart function ?-IV) Grade I NYHA rating) aminotransferase increased to more than 2 times the upper limit of the normal range severe thrombocytopenia (PLT<10×109/L) abnormal coagulation function or active digestion within three months Blood patients (8) accompanied by wasting diseases such as tuberculosis or a history of mental illness (9) Women who are pregnant or preparing to become pregnant or breast-feeding (10) Participants who are participating in other interventional clinical trials or have participated in other clinical trials within 12 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| urinary albumin?to?creatinine ratio;urinary albumin excretion rates; | — |
Secondary
| Measure | Time frame |
|---|---|
| 24-hour urinary protein quantification;Quality of life score;HbA1c;Blood biochemistry;TCM syndrome integral; | — |
Countries
China
Contacts
Public ContactSun Weiwei
Dongzhimen Hospital Beijing University of Chinese Medicine
Outcome results
None listed